Remedy Robotics said on 16 November 2026 that it had raised $62 million in a Series B round led by DCVC, according to a report on unite.ai. The company says the money will advance clinical development of its N1 robotic system. The N1 is still in development and is not available for sale or clinical use in any jurisdiction.

The round

DCVC led the round. UC Investments, the University of California’s investment office, is a new investor, along with Skip Capital and Hostplus, an Australian pension fund. Existing investors Build Collective, Blackbird, Divergent Capital and KdT Ventures increased their backing. The article does not state a valuation.

What the N1 is meant to do

Remedy describes the N1 as an AI-powered robotic system built to “complete entire endovascular procedures robotically.” It is designed to operate on site, remotely or autonomously across neurovascular, coronary and peripheral vascular care.

What the company says

Chief executive Dr David Bell said: “Endovascular intervention is the gold standard treatment for stroke.” He said access to it “remains limited to a small number of hospitals,” which the company is trying to address.

Sources and notes

Read in full: unite.ai, which quotes the company’s announcement. Lens did not open Remedy’s own release or any other outlet’s report, so the round size, lead and investor list rest on this one article. The N1’s status is as stated in that article; Lens did not verify it.

Image: a surgeon performing robot-assisted surgery, used as a stand-in. It is not Remedy’s N1. Photo by Navy Medicine, public domain, via Wikimedia Commons.